

# PRODUCT INFORMATION




## Mycro 3

Item No. 37767

**CAS Registry No.:** 944547-46-0  
**Formal Name:** 5-[[[7-(chlorodifluoromethyl)-5-(2-furanyl)pyrazolo[1,5-a]pyrimidin-2-yl]carbonyl]amino]-1-phenyl-1H-pyrazole-4-carboxylic acid, ethyl ester

**MF:** C<sub>24</sub>H<sub>17</sub>ClF<sub>2</sub>N<sub>6</sub>O<sub>4</sub>  
**FW:** 526.9  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Mycro 3 is supplied as a solid. A stock solution may be made by dissolving the mycro 3 in the solvent of choice, which should be purged with an inert gas. Mycro 3 is soluble in DMSO.

### Description

Mycro 3 is an inhibitor of the protein-protein interaction between c-Myc and c-Myc associated protein (Max; IC<sub>50</sub> = 40 μM).<sup>1</sup> It is also an inhibitor of Max dimerization (IC<sub>50</sub> = 88 μM). Mycro 3 selectively reduces the viability of c-Myc-expressing TGR-1 fibroblasts over c-Myc-null HO15.19 fibroblasts (IC<sub>50</sub>s = 0.25 and 9 μM, respectively).<sup>2</sup> It decreases tumor weight in PANC-1 and MIA PaCa-2 pancreatic cancer mouse xenograft models when administered at a dose of 100 mg/kg per day. Mycro 3 (5 mg/kg every three days), in combination with docetaxel (Item No. 11637) or abiraterone (Item No. 9002768), reduces tumor volume and improves survival in an LNCaP prostate cancer mouse xenograft model.<sup>3</sup>

### References

1. Kiessling, A., Wiesinger, R., Sperl, B., *et al.* Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. *ChemMedChem* **2**(5), 627-630 (2007).
2. Stellas, D., Szabolcs, M., Koul, S., *et al.* Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. *J. Natl. Cancer Inst.* **106**(12), dju320 (2014).
3. Li, F., Zhao, Z., Zhang, Z., *et al.* Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner. *BMC Cancer* **21**(1), 1112 (2021).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM